Subsequent Events	6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On July 7, 2023, the Company settled its forward contract liability by issuing the underlying Series A Preferred Stock to the former Spyre shareholders. On July 27, 2023, the Company announced that it has entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency, to Immedica for $15.0 million in upfront cash proceeds and up to $100.0 million in contingent milestone payments. The sale of pegzilarginase to Immedica supersedes and terminates the previous license agreement between the Company and Immedica. The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the FDA, among other events. The upfront payment and contingent milestone payments if paid, net of expenses and adjustments, will be distributed to holders of Aeglea’s CVR pursuant to the CVR Agreement resulting from the Asset Acquisition. On August 7, 2023, the Company terminated its building lease in Austin, Texas. The negotiated termination agreement obligates the Company to pay the lessor a $2.0 million termination fee in exchange for releasing the Company of all further obligations under the lease.

Subsequent Events

6 Months Ended

Jun. 30, 2023

14. Subsequent Events

On July 7, 2023, the Company settled its forward contract liability by issuing the underlying Series A Preferred Stock to the former Spyre shareholders.

On July 27, 2023, the Company announced that it has entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency, to Immedica for $15.0 million in upfront cash proceeds and up to $100.0 million in contingent milestone payments. The sale of pegzilarginase to Immedica supersedes and terminates the previous license agreement between the Company and Immedica.

The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the FDA, among other events. The upfront payment and contingent milestone payments if paid, net of expenses and adjustments, will be distributed to holders of Aeglea’s CVR pursuant to the CVR Agreement resulting from the Asset Acquisition.

On August 7, 2023, the Company terminated its building lease in Austin, Texas. The negotiated termination agreement obligates the Company to pay the lessor a $2.0 million termination fee in exchange for releasing the Company of all further obligations under the lease.